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Abstract
ARLTS1 is a recently characterized tumor suppressor gene at 13q14.3, a region frequently deleted in both sporadic and
hereditary prostate cancer (PCa). ARLTS1 variants, especially Cys148Arg (T442C), increase susceptibility to different cancers,
including PCa. In this study the role of Cys148Arg substitution was investigated as a risk factor for PCa using both genetic
and functional analysis. Cys148Arg genotypes and expression of the ARLTS1 were explored in a large set of familial and
unselected PCa cases, clinical tumor samples, xenografts, prostate cancer cell lines and benign prostatic hyperplasia (BPH)
samples. The frequency of the variant genotype CC was significantly higher in familial (OR=1.67, 95% CI=1.08–2.56,
P=0.019) and unselected patients (OR=1.52, 95% CI=1.18–1.97, P=0.001) and the overall risk was increased (OR=1.54,
95% CI=1.20–1.98, P=0.0007). Additional analysis with clinicopathological data revealed an association with an aggressive
disease (OR=1.28, 95% CI=1.05-‘, P=0.02). The CC genotype of the Cys148Arg variant was also contributing to the
lowered ARLTS1 expression status in lymphoblastoid cells from familial patients. In addition significantly lowered ARLTS1
expression was observed in clinical tumor samples compared to BPH samples (P=0.01). The ARLTS1 co-expression signature
based on previously published microarray data was generated from 1587 cancer samples confirming the low expression of
ARLTS1 in PCa and showed that ARLTS1 expression was strongly associated with immune processes. This study provides
strong confirmation of the important role of ARLTS1 Cys148Arg variant as a contributor in PCa predisposition and a
potential marker for aggressive disease outcome.
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Introduction
ADP-ribosylation factor-like tumor suppressor gene 1 (ARLTS1),
also known as ADP-ribosylation factor-like protein 11 (ARL11), is a
newlycharacterizedgenelocatedatlocus13q14.3.ARLTS1belongs
to the ADP-ribosylation factor (ARF)-ARF-like (ARL) family of the
Ras protein superfamily [1]. ARFs are guanine-nucleotide-binding
proteins which are criticalcomponentsof several different eukaryotic
vesicle trafficking pathways. As with other members of the Ras
superfamily, ARFs function as molecular switches by cycling
between inactive GDP- and active GTP-bound conformations [2].
ARLTS1 has been characterized as an intracellular protein having
tissue specific expression in the lung and leucocytes. ARLTS1
variants, such as the nonsense polymorphism Trp149Stop (G446A)
and missense polymorphism Cys148Arg (T442C), have been
suggested to have a role in different cancers [3–6].
Prostate cancer is the most frequently diagnosed cancer in males
in many countries, including Finland. Aging and improved
diagnostics most evidently increase the number of new cases, but
the incidence is influenced also by some unknown factors. Growing
number of new cases create pressure to health care system and new
tools for PCa diagnostics, prognostics and treatment are required,
especially to avoid over treatment and unnecessary biopsies. During
the last several years there has been extensive research in PCa
etiology and genome-wide association studies have revealed several
common low penetrance genetic alterations. The association of
these variants with clinicopathologic features and prognosis remains
unclear and results are lacking clinical implications.
We recently showed a significant association withCys148Arg
(T442C) variant and the risk of PCa [7]. Further evaluation of this
variant is warranted to increase the power of the association and
study the functional role of the variant in PCa. More samples are
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outcome and a potential role in predictive biomarker of PCa.
Besides the genetic variants, DNA copy number aberrations are
one of the most frequently observed genetic changes in familial
and sporadic PCa [8–10]. In most of the cases target genes for the
aberrations are not fully identified. Interestingly, allelic imbalance
(AI) has been detected at 13q14.2-13q14.3, and it is an important
event in the progression of localized PCa [11]. Differences of
13q14 loss of heterozygosity (LOH) in different PCa groups could
also be used to distinguish clinically insignificant PCa [12,13].
In this study we analyzed the role of ARLTS1 in more detail,
especially the role of Cys148Arg (T442C) in PCa risk. Chromo-
somal aberration in 13q14.3 was analyzed with aCGH to evaluate
the ARLTS1 copy number changes in PCa xenografts and cell
lines. The expression of ARLTS1 was studied in clinical tumor
samples, BPH samples and also co-expression data form previously
published data was analyzed.
Methods
Study population
All samples collected are of Finnish origin. Identification and
collection of the Finnish HPC families have been described
elsewhere [14]. The familial samples genotyped in this study had
at least one affected first or second degree relative. The clinical
characteristics of the familial patients can be found in Table S1.
The unselected consecutive prostate cancer patients were
diagnosed with PCa between 1999 and 2005 in the Department
of Urology at Tampere University Hospital. The hospital is a
regional referral center in the area for all patients with PCa, which
results in an unselected, population-based collection of patients.
The clinical characteristics of the consecutive unselected PCa can
be found in Table S1.
A set of benign prostatic hyperplasia (BPH) cases was also used
in this study. The diagnosis of this BPH cohort was based on
lower-urinary tract symptoms, free uroflowmetry, and evidence of
increased prostate size obtained by palpation or transrectal
ultrasound. If PSA was elevated or digital rectal examination or
transrectal ultrasound showed any abnormality indicative of PCa,
the patients underwent biopsies to exclude diagnoses of PCa, high-
grade prostate intraepithelial neoplasia (PIN), atypical small acinar
cell proliferation (ASAP), or suspicion of malignancy.
Clinical prostate tumors were obtained from Tampere Univer-
sity Hospital (Tampere, Finland) including freshly frozen prostate
tumor specimens representing benign prostate hyperplasia (BPH,
n=14), androgen-dependent (n=14) and hormone-refractory
(n=6) carcinomas. The specimens were histologically examined
for the presence of tumor cells using H&E staining. Only samples
containing .60% cancerous or hyperplastic epithelial cells were
selected for the analyses. The BPH samples were obtained from
prostatectomy specimens from cancer patients and were histolog-
ically verified not to contain any cancerous cells. Samples from
hormone-refractory carcinomas were obtained from transurethral
resections of prostate (TURP) from patients experiencing urethral
obstruction despite ongoing hormonal therapy. The time from the
beginning of hormonal therapy to progression (TURP) varied
from 15 to 60 months. The use of clinical tumor material
was approved by the Ethical Committee of Tampere University
Hospital.
The control samples consisted of DNA samples from anony-
mous, voluntary, and healthy blood donors obtained from the
Blood Center of the Finnish Red Cross in Tampere. The EDTA
blood samples used as reference in Q-RT-PCR were from healthy
anonymous donors.
Patient information and samples were obtained with full
informed consent. The study was performed under appropriate
research permissions from the Ethics Committees of the Tampere
University Hospital, Finland, as well as the Ministry of Social
Affairs and Health in Finland.
Cell lines and xenografts
The PCa cell lines LNCaP, DU145, PC-3, NCI-660 and 22Rv1
were obtained from American Type Culture Collection (Manassas,
VA, USA), whereas LAPC-4 was kindly provided by Dr. Charles
Sawyers (UCLA, Los Angeles, CA), and the VCaP cell line was
provided by Dr. Jack Schalken (Radboud University Nijmegen
Medical Centre, Nijmegen, the Netherlands). All cell lines were
cultured under recommended conditions. PrEC primary cells were
obtained from Lonza (Walkersville, MD, USA). EP156T is an h-
tert immortalized normal prostate epithelial cell line [15] that was
made available by one of the authors (O.K.). DNA was extracted
according to standard laboratory protocols and total RNA was
extracted with the TRIzol reagent (Invitrogen Life Technologies,
Carlsbad, CA, USA).
Nineteen human PCa xenografts of the LuCaP series used in
direct sequencing and fifteen of them used in Q-RT-PCR were
made available by one of the authors (R.L.V.) and have been
described elsewhere [16,17].
The lymphoblastoid cell lines were derived by Epstein-Barr
virus transformation of peripheral mononuclear leucocytes from
patients. Lymphoblastoid cell lines were grown in RPMI-1640
medium (Lonza, Walkersville, MD, USA) supplemented with 10%
fetal bovine serum (Sigma-Aldrich, St. Louis, MO, USA) and
antibiotics. Cell pellets were snap-frozen and total RNA was
extracted from cells with TrizolH according to the instructions of
the manufacturer (Invitrogen, Carlsbad, CA, USA).
Mutation screening
Mutation screening of the genomic DNA was performed by
direct sequencing. Sequencing was performed in an Applied
Biosystems 3130xl Genetic Analyzer (Life Technologies Corpora-
tion, Carlsbad, CA, USA) according to the instructions of the
manufacturer. Primers and PCR conditions used in the mutation
screening are available upon request.
Genotyping
Genotyping was done with the Custom TaqManH SNP
Genotyping Assay using the ABI Prism 7900HT sequence
detection system (Life Technologies Corporation, Carlsbad, CA,
USA) according to the manufacturer’s instructions. Primers and
probes for the Cys148Arg (T442C) SNP rs3803185 were supplied
by Applied Biosystems via the File Builder 3.1 software.
Quantitative real-time reverse transcription-PCR
Gene expression analyses were done using LightCyclerH
(Roche, Mannheim, Germany) and Bio-Rad CFX96
TM Real-
Time PCR detection system (Bio-Rad Laboratories, Hercules, CA,
USA). Total RNA was isolated from cell lines, clinical tumor
samples and xenografts as described previously [18,19]. RNA from
cell lines was reverse transcribed into first-strand cDNA using
SuperScript
TM III First-Strand Synthesis SuperMix kit (Invitro-
gen, Carlsbad, CA, USA) and random hexamers. RNA from
clinical tumor samples and xenografts was reverse transcribed as
described previously [18,19]. Normal human prostate RNA was
obtained from Ambion (Cambridgeshire, United Kingdom). For
the LightCyclerH analyses, primers and probe sets were obtained
from TIB MolBiol (Berlin, Germany). The PCR reactions were
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PLUS HybP-
robe kit (Roche, Mannheim, Germany). LightCyclerH software
(Roche, Mannheim, Germany) was used for data analysis. The
TaqMan assay for ARLTS1 was used for Bio-Rad analyses. The
primers and probes were obtained from TIB MolBiol (Berlin,
Germany). Bio-Rad’s iQ Supermix was used for the PCR reactions
and CFX Manager Software
TM version 1.6 for data analysis.
Expression levels of ARLTS1 were normalized against the housekeep-
ing gene TBP (TATA box binding protein) or against RNA levels.
TBP was chosen as the reference gene, because there are no known
retropseudogenesforit,and the expression of TBP islower than that of
many commonly used, abundantly expressed reference genes [20].
Western blotting
Cells were lysed in a buffer containing 50 mM Tris-HCl
pH 7.5, 150 mM NaCl, 0.5% Triton-X-100, 1 mM DTT, 1 mM
PMSF and 16 complete protease inhibitor cocktail (Roche,
Mannheim, Germany). Lysates were sonicated 4630 s with
Bioruptor instrument (Diagenode, Liege, Belgium) and the cellular
debris was removed by centrifugation. Proteins were separated by
polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to
PVDF membrane (Immobilon-P; Millipore, Billerica, MA, USA).
Primary antibodies used were anti-ARL11 (Aviva Systems Biology,
San Diego, CA, USA) and anti-actin (pan, clone ACTN05,
Neomarkers, Fremont, CA, USA), which were detected by HRP-
conjugated secondary antibodies (DAKO, Denmark) and Western
blotting luminol reagent (Santa Cruz Biotechnologies, CA, USA)
by autoradiography.
Array comparative genomic hybridization
Array comparative genomic hybridization (aCGH) was per-
formed on PCa cell lines and xenografts with the Human Genome
CGH Microarray Kit 244A (Agilent, Santa Clara, CA, USA), and
as described in Sarama ¨ki OR et al, 2006 [19].
Statistical analysis
Association of the Cys148Arg (T442C) variant was tested by
logistic regression analysis using SPSS statistical software package
(SPSS 15.0; SPSS Inc, Chicago, IL, USA). Association with
clinical and pathological features of the disease (age at onset, PSA
value at diagnosis, T, N, and M-stage, WHO grade and Gleason
score) was tested among familial and unselected PCa cases by
the Kruskal–Wallis test, Fisher’s exact test, and t-test included in
R ‘‘Stats’’ package. PCa patients were classified as having an
aggressive disease if they had any of the following characteristics: a
locally advanced or metastatic tumor (stage T3, T4, N1, or M1,
based on pathology if radical prostatectomy was done; otherwise,
clinical stage), tumor Gleason grade at diagnosis $7, poorly
differentiated grade (WHO grade III, if no Gleason grade
available) or pretreatment PSA at diagnosis $20 ng/ml.
Co-expression analysis of ARLTS1 in previously published
microarray datasets
The ARLTS1 co-expression signature was generated from the
GeneSapiens [21] database of mRNA expression. ARLTS1
expression among 1587 tumor samples and among 497 normal
samples was determined. We used Pearson correlation to identify
genes that positively and negatively correlated with ARLTS1
among normal samples and tumor samples.
Functional annotation analysis
Gene sets were explored for enrichment of functional
annotation categories such as gene ontology (GO), using tools
within the EASE program (http://david.abcc.ncifcrf.gov/) [22].
The top 100 genes that were positively correlating with ARLTS1
among normal samples were checked for enriched Gene
Ontology.
Results
The whole coding region of ARLTS1 was previously screened in
a total of 164 familial PCa patients and in a total of 377 unselected
PCa patients, as well as in 381 control samples [7]. Here the
Cys148Arg (T442C) variant was further genotyped in 48 familial
PCa patients, 1471 unselected PCa patients, 375 BPH patients and
379 controls. By utilizing our previous data and genotyping more
familial and unselected PCa cases, we validated a statistically
significant association between Cys148Arg (T442C) and PCa risk
(Table 1). When considering the familial PCa cases, and the
association with risk allele C, the homozygous form CC reached a
P value 0.019 (OR 1.67; 95% CI 1.08–2.56). Within unselected
cases, the risk was also significant (OR 1.52, 95% CI 1.18–1.97,
P=0.001). When combining the datasets of familial and
unselected cases (2060 samples total), the Cys148Arg (T442C)
variant was found to be associated significantly with PCa risk (OR
1.54, 95% CI 1.20–1.98, P=0.0007). Significant association was
only found when comparing the frequencies of the homozygous
form of the risk allele C to the frequencies of the homozygous form
of the wild-type allele T. No association was found between the
frequency of CC and BPH (Table 1).
When studying the segregation of Cys148Arg (T442C) CC
genotype in 86 families where the index was detected as a carrier,
complete segregation of the variant CC with cancer phenotype
was seen in one family (family 427 in Fig. 1). In the rest of the
families segregation was incomplete, yet indicating a clear
association with ARLTS1 genotype CC or TC and cancer
phenotype (families 402 and 408 in Fig. 1).
Direct sequencing was used to examine the frequencies of
ARLTS1 variants in clinical prostate tumors. In the clinical
prostate carcinomas, we found variants at four sites, Gly65Val
(G194T), Pro131Leu (C392T), Cys148Arg (T442C) and
Trp149Stop (G446A) (Table 2). At the Cys148Arg (T442C) site,
the frequency of the cancer associated risk genotype CC was
relatively high (28.3%) compared to the combined frequency of
familial and unselected cases 21.2% (Table 1). However, the
highest frequency of Cys148Arg (T442C) CC genotype was
detected in xenograft samples (42.1%). This is intriguing since
LuCaP xenograft samples are considered as a very homogenous
representation of PCa.
To investigate the role of Cys148Arg (T442C) genotype in
ARLTS1 expression we selected 24 familial patients, including
eight from each genotype group TT, CT and CC. Expression
analyses by Q-RT-PCR were carried out by using the RNA
extracted from lymphoblastoid cell lines of the patients. ARLTS1
mRNA was expressed differentially between the three genotype
groups (Fig. 2). The expression was significantly reduced among
patients carrying the CC genotype (P=0.02).
ARLTS1 expression levels were also analyzed in fifteen LuCaP
xenograft samples, six PCa cell lines, two prostate epithelial cell
lines and in RNA from normal prostate sample. Among the
analyzed xenograft samples, a significant reduction in ARLTS1
expression was observed in two of the samples (13%) when
compared to its expression in normal prostate sample (Fig. 3A).
Total loss of expression was seen in 11 (73%) of the xenograft
samples (Fig. 3A). Two of the xenograft samples, LuCaP23.1 and
LuCaP49, had higher ARLTS1 expression levels compared to the
normal tissue. Six of the fourteen (43%) ARLTS1 down-regulated
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variant. When array comparative genomic hybridization (aCGH)
was performed using these samples, 12/15 xenograft samples
showed a loss on the chromosomal region of 13q14.3 (Fig. 3A).
In PCa cell lines, 5/6 (83%) showed a decreased or lost
expression of ARLTS1 when compared to normal prostate RNA
(Fig. 3A). An ARLTS1 locus deletion at 13q14.3 was found in PC-
3, VCaP, LNCaP and DU-145. Among these, the latter also had
the CC genotype for Cys148Arg (T442C). Interestingly, the
Cys148Arg (T442C) variant was the only ARLTS1 variant found in
any of the PCa cell lines. Prostate epithelial cell line EP156T
showed loss of expression. These results likely indicate that
ARLTS1 expression is low in the PCa epithelial cells.
ARLTS1 expression was also assessed with the same approach in
a panel of fourteen BPH tissue samples, fourteen primary and six
hormone-refractory tumor samples (Fig. 3B). ARLTS1 expression
was signinificantly lower (P=0.01) in clinical tumors compared to
BPH samples, which further supports its role as a tumor
suppressor protein (Fig. 3B).
In clinical prostate tumors, the existence of LOH was studied.
Germline DNA from patients carrying the Cys148Arg (T442C)
variant was analyzed by direct sequencing. Sequencing results
showed that in two cases (samples 261 and 530) the T allele in
blood had been replaced with a C allele in cancer tissue (Fig. 3C)
which suggests a role for ARLTS1 in tumor suppression i.e.,
inactivation of both alleles in carcinogenesis. When clinical
parameters (WHO grade, Gleason and T-scores) were examined,
one of the two variant-carrying ‘‘LOH-patients’’ had a Gleason
score of 9 and WHO grade of 3, indicating an aggressive form of
the disease. The other case had a WHO grade of 3 but no Gleason
score was available.
ARLTS1 expression was further determined by Western
blotting (Fig. 4). Cell lysates were available from six prostate
cancer cell lines, (22Rv1, LAPC-4, PC-3, VCaP, LnCaP, DU-145)
and from the normal prostate epithelial cell line EP156T.
ARLTS1 expression was highly convergent to ARLTS1 mRNA
status showed in Fig. 3A. As expected, cell lines LnCaP, DU-145
and EP156T showed negative expression. In prostate cancer cell
lines 22Rv1 and PC-3 ARLTS1 expression was corresponding to
relative mRNA expression values, whereas in PCA cell line
LAPC4 protein expression status was lower than the mRNA
expression level. PCA cell line VCaP showed the highest ARLTS1
expression which was not corresponding to negative relative
expression status seen in Q-RT-PCR.
When clinical characteristics (age at diagnosis, PSA value at
diagnosis, T, N, and M-stage, WHO grade and Gleason score)
were included in the analyses of germline genotype data, the
CC genotype was significantly associated with a younger age at
diagnosis and PSA value (P=0.05 and P=0.03, respectively)
among the unselected material. This phenomenon was also
observed in our previous study where the CC genotype of
Cys148Arg (T442C) was associated with high Gleason scores
(P=0.01) and high PSAs ($7) at diagnosis (P=0.05) [7]. When
the correlation between aggressive disease status and the
occurrence of the CC genotype was examined, we found
a statistically significant association (P=0.02) among the
unselected cases (Table 3). Within familial PCa cases, no
association was found between the CC genotype at the
Cys148Arg (T442C) locus and any of the clinical variables or
with aggressive PCa.
ARLTS1 expression in the different tissues of the body is shown
in Figure S1. The figure illustrates that ARLTS1 is highly expressed
Table 1. Association of the ARLTS1 Cys148Arg variant with prostate cancer and benign prostatic hyperplasia.
Cases Controls
n (%) n (%) OR* 95% CI P
Prostate cancer patients, all 2060 760
TT 615 (29.9) 249 (32.8)
TC 1008 (48.9) 396 (52.1) 1.03 0.85–1.24 0.753
CC 437 (21.2) 115 (15.1) 1.54 1.20–1.98 0.0007
TC+CC 1445 (70.1) 511 (67.2) 1.15 0.96–1.37 0.137
Familial prostate cancer patients 212 760
TT 65 (30.7) 249 (32.8)
TC 97 (45.7) 396 (52.1) 0.94 0.66–1.33 0.723
CC 50 (23.6) 115 (15.1) 1.67 1.08–2.56 0.019
TC+CC 147 (69.3) 511 (67.2) 1.1 0.79–1.53 0.563
Unselected prostate cancer patients 1848 760
TT 550 (29.8) 249 (32.8)
TC 911 (49.3) 396 (52.1) 1.04 0.86–1.26 0.676
CC 387 (20.9) 115 (15.1) 1.52 1.18–1.97 0.001
TC+CC 1298 (70.2) 511 (67.2) 1.15 0.96–1.38 0.131
Benign prostatic hyperplasia 375 760
TT 110 (29.3) 249 (32.8)
TC 203 (54.1) 396 (52.1) 1.16 0.88–1.54 0.299
CC 62 (16.5) 115 (15.1) 1.22 0.83–1.79 0.306
TC+CC 265 (70.7) 511 (67.2) 1.17 0.90–1.54 0.243
*compared to TT homozygotes.
doi:10.1371/journal.pone.0026595.t001
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expression analysis illustrate a strong association with immune
system processes, revealing an enrichment score for the cluster of
6.67 and a p-value of 2.1e-7. These results were generated from
the top 100 genes with a correlation value greater than 0.3 among
normal samples. Among cancer samples, the category of immune
system processes had the highest enrichment score 14.89 with a p-
value of 5.3e-21 and adjusted Benjamin score of 2.8e-17. We did
not identify any strong gene ontology associated with the top 100
genes that were negatively correlated with ARLTS1 among cancer
samples. We confirmed our findings using a separate dataset from
expo (IGC: Expression Project for Oncology. 2008 [http://www.
intgen.org/expo.cfm]). The results illustrate that 56% of the genes
were commonly identified to positively correlate with ARLTS1 in
either dataset comprised of cancer samples. The genes with a
positive correlation above 0.3 identified in the intersection yielded
a very strong gene ontology enrichment score of 18.12 for immune
system process with a p-value of 2.1e-24 as shown in Figure S2.
Gene expression among PCa specimens is shown to be very low
for ARLTS1. We could not reliably establish any significant link to
PCa for ARLTS1 using gene expression data due to low expression
levels.
Figure 1. Examples of segregation analysis in three ARLTS1
Cys148Arg (T442C) variant-positive families with prostate
cancer. Squares represent males; circles represent females. Open
symbols indicate no neoplasm, and filled symbols denote prostate
cancer cases. +indicates the presence of the T442C variant in the DNA
sample of the family members, followed by the actual genotype. An
arrow indicates the individual initially screened for ARLTS1 sequence
variants. Age at diagnosis for prostate cancer patients (in years) is
indicated below the symbol for each family member. An asterisk (*)
denotes the persons with no sample available.
doi:10.1371/journal.pone.0026595.g001
Table 2. Observed ARLTS1 variants and their frequencies in clinical prostate tumors and LuCap xenografts.
Nucleotide change Amino acid change Genotype Clinical prostate tumors n (out of 53, %) Xenografts n (out of 19, %)
G194T Gly65Val GG 52 (98.1) 19 (100)
GT 1 (1.9) 0 (0)
TT 0 (0) 0 (0)
C392T Pro131Leu CC 43 (81.1) 19 (100)
CT 10 (18.9) 0 (0)
TT 0 (0) 0 (0)
T442C Cys148Arg TT 23 (43.4) 7 (36.8)
TC 15 (28.3) 4 (21.1)
CC 15 (28.3) 8 (42.1)
G446A Trp149Stop GG 52 (98.1) 18 (94.7)
GA 1 (1.9) 1 (5.3)
AA 0 (0) 0 (0)
doi:10.1371/journal.pone.0026595.t002
Figure 2. The relative expression of ARLTS1 in Cys148Arg
(T442C) genotyped lymphoblastoid cell lines. Determined by Q-
RT-PCR. *, P,0.05. Columns, mean of eight individuals; bars, SD.
doi:10.1371/journal.pone.0026595.g002
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The ARLTS1 gene and ARLTS1 polymorphisms have been
shown to have a role in the pathogenesis of many cancers. The
nonsense polymorphism at the end of the coding region has been
revealed to predispose to familial cancer [8]. Functional analyses
of the truncated protein have indicated that the Trp149Stop
variant might affect apoptosis and tumor suppression. Another
ARLTS1 variant, the missense polymorphism Cys148Arg (T442C),
and especially the CC genotype, has been found to be significantly
associated with high-risk familial breast cancer [4]. The same
variant was also found to be associated with predisposition to
melanoma [5]. The roles of ARLTS1 variants have also been
studied with colorectal cancer [23] and chronic lymphocytic
leukemia (CLL) [24] but no associations have been found.
In the present study, we showed an association with the ARLTS1
Cys148Arg (T442C) variant and elevated PCa risk, validating our
previous results [7]. Previously, we sequenced 164 familial and 377
unselected PCa samples together with 809 controls, and
Cys148Arg (T442C) showed significant association with PCa risk
(OR 1.19; 95% CI 1.02–1.39, P=0.020) but the significance did
not hold when the data were subdivided into familial and
unselected cases. However, when the C allele was assumed to be
recessive, all data (familial and unselected) showed significant
association between the CC genotype and PCa risk (P=0.005).
Here were genotyped more familial and unselected PCa cases and
Cys148Arg (T442C) revealed a statistically significant association
with PCa risk among both familial (OR=1.67, 95% CI=1.08–
2.56, P=0.019) and unselected PCa patients (OR=1.52, 95%
CI=1.18–1.97, P=0.001). In the combined data set of both
familial and unselected cases, the overall risk was even more
increased (OR=1.54, 95% CI=1.20–1.98, P=0.0007). The fact
that previous analysis did not hold when divided to subclasses
could therefore be explained by the size of the study. The current
study has a power of approximately 100% to detect association
compared to 94% of the previous study. Further follow-up with
larger sample size would likely make the association even stronger.
We found no association between this variant and BPH, suggesting
that role of the Cys148Arg (T442C) is minor and the cancer
predisposing effect emerges only in more advanced cases,
especially those with an aggressive PCa status. Alternatively,
BPH and PCa are independent events or at least ARLTS1 is not
consequential for BPH transformation to PCa. The longer follow-
up of the BPH patients is needed to assess the question whether the
patients carrying CC genotype (16%) are the ones developing
cancer later on.
Only the homozygous form of the C allele of the Cys148Arg
(T442C) variant resulted in an association with PCa risk when
compared to the TT genotype. This supports the results from
previous studies with breast cancer [4] that showed that C is the
risk allele while the T allele has a protective or neutral effect on
carcinogenesis. ARLTS1 Cys148Arg (T442C) in particular has a
predisposing effect on sporadic PCa. Further, the Cys148Arg was
the only ARLTS1 variant observed at a greater frequency among
PCa tissue samples and xenografts, where the frequencies were
28.3% and over 40 percent, respectively. This also indicates a
likely role for ARLTS1 in prostate carcinogenesis. Interestingly, a
total absence of Trp149Stop (G446C) was observed both in
clinical tumor samples and in xenografts indicating that this
variant has not an important role in PCa development.
The control population in our study was not in Hardy-
Weinberg equilibrium (HWE), suggesting that Cys148Arg might
be a novel variant. In our data, an excess of heterozygotes was
observed which may indicate the presence of over dominant
selection or the occurance of outbreeding. The phenomenon of
heterozygous advantage allows for natural selection to maintain
the polymorphism. The same control population has been used
many times in different analyses, and never before has it been
discordant from HWE [25]. Interestingly, in the Sub-Saharan
African population, the CC genotype does not exist, and in the
Asian population it is only present in a small fraction (http://www.
ncbi.nlm.nih.gov). Only within the European population does CC
exist at a greater proportion. Considering the possible role of
ARLTS1 in the immune system, it may be that the CC genotype
has provided a protective effect among Europeans. HW
disequilibrium among the controls is not either result of
genotyping error because direct sequencing was previously used
to genotype 164 of the familial PCa samples and the genotypes
matched with the TaqMan assay results. Furthermore, the same
assay was used to genotype all the cancer samples and controls.
Quantitative reverse-transcriptase-polymerase-chain-reaction
assay (Q-RT-PCR) showed lowered ARLTS1 expression in most
of the clinical PCa samples, compared to BPH samples. This is
consistent with the previous findings; ARLTS1 expression has also
been detected to be very low or absent in lung carcinomas and
CLL cells [8,26], as well as in ovarian primary tumors and cell
lines [27], when compared with the levels of their normal
counterparts. Here, using Q-RT-PCR, we used commercially
available normal prostate RNA from a 72 year-old male. With
respect to PCa disease progression, we could assume that at the
age of 72 there might be some changes in the prostatic tissue, and
use of control RNA from a younger male might lead to even better
results concerning comparisons of ARLTS1 expression status in
normal and diseased samples.
Western analysis of prostate cancer cell lines for levels of
ARLTS1 protein was in most part convergent with the ARLTS1
mRNA levels. However, in one sample with 13q14.3 deletion
(VCaP), high protein expression was detected. This divergent
result may originate from several reasons and needs further
investigation. ARLTS1 tumor suppressor gene may have dupli-
Figure 4. The levels of ARLTS1 protein by Western blotting.
Protein expression status in six prostate cancer cell lines and in one
normal prostate epithelial cell line. Actin is shown as a loading control.
ARL11 expected/observed Mw 21.4 kDa. A non-specific band is marked
with an asterisk (*).
doi:10.1371/journal.pone.0026595.g004
Figure 3. Relative expression of ARLTS1 in A, LuCaP xenografts, prostate cancer cell lines, prostate epithelial cells and in normal
prostate and B, in BPH and clinical tumor samples, as determined by Q-RT-PCR. The Cys148Arg (T442C) genotype as well as the
choromosomal aberration is shown. C, Cys148Arg (T442C) variant in two clinical cancer tissue samples and in two normal blood DNA (sequences are
in reverse orientation). * determined as in Sarama ¨ki OR et al., 2006.
doi:10.1371/journal.pone.0026595.g003
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However, these protein expression results further confirm that
ARLTS1 expression is low in the PCa epithelial cells.
The suggested mechanisms behind the reduced or absent
ARLTS1 expression are variable, including promoter hypermethy-
lation or LOH. It has been confirmed that in lung cancer cell lines
and in ovarian carcinomas ARLTS1 is down-regulated due to
DNA methylation in its promoter region [26,27]. ARLTS1
restoration by adenoviral transduction induced apoptosis. Finally,
re-expression of ARLTS1 suppressed ovarian and lung cancer
tumorigenity in nude mice. We were able to show that LOH exists
also in PCa samples, meaning that heterozygous deletions may
affect ARLTS1 expression levels. ARLTS1 resides at 13q14.3, a
region that has been reported to be deleted in a variety of
hematopoietic and solid tumors [8], including PCa. Future
investigations include whether reduced ARLTS1 expression in
PCa may be due to hypermethylation.
Chronic or recurrent inflammation has been implicated in the
initiation and development of several human cancers, including
those of the stomach, liver, colon, and urinary bladder and a role
for chronic inflammation in the etiology of PCa has been proposed
[28]. The source for prostatic inflammation is unclear, but it has
been suggested that it may be directly related to prostate infecting
agents (such as sexually transmitted organisms and viruses), dietary
factors and oxidative stress, urine reflux, chemical and physical
trauma or a combination of these. Recently experimental evidence
was provided by Schlaberg R et al that xenotropic murine
leukemia virus-related virus (XMRV) was present in malignant
prostatic cells and was significantly associated with more aggressive
tumors [29]. Susceptibility genes related to PCa might function in
host immune responses and protection against cell and DNA
damage caused by oxidative agents. For example, two suggested
susceptibility risk genes for hereditary PCa, RNASEL and MSR1,
are both involved with innate immunity. Lymphoblastoid cell lines
represent an essential component of the immune response, so this
result may indicate that ARLTS1 has a function in immune system
processes.
Alterations in important molecular pathways involved in PCa
have been implicated in proliferative inflammatory atrophy (PIA)
and prostatic intraepithelial neoplasia (PIN) lesions. Tumor
suppressor genes NKX3.1 [30], CDKN1B which encodes p27
[28,31] and the phosphatase and tensin homologue (PTEN) [32]
are highly expressed in normal prostate epithelium and have
shown to be down-regulated or absent in PIN and PCa. Since
ARLTS1 acts as a tumor suppressor protein and has a decreased
expression in PCa, these recent findings are in line with the results
from other suggested PCa tumor suppressor proteins.
Previously it has been shown that ARLTS1 induces apoptosis in
lung cancer cells [8,26] and in ovarian carcinoma [27]. In the case
of prostatic inflammation and antigen engagement, the need for
apoptosis increases and the processes of the immune system,
together with endogenous inflammatory cells (such as T and B
lymphocytes) become activated. Here we showed that in the
lymphoblastoid cell lines of PCa patients, ARLTS1 expression was
significantly decreased among the CC carrying patients compared
to the wild-type allele T carrying patients. The lymphoblastoid cell
lines were derived by Epstein-Barr virus transformation of
peripheral mononuclear leucocytes from patients, indicating that
these cells have encountered antigen stimuli via viral infection.
The CC carrying patients had a low ARLTS1 expression status
suggesting that ARLTS1 function is decreased due to this risk
genotype and consequently this leads to decreased apoptosis. This
may indicate that the Cys148Arg (T442C) CC genotype
contributes to the immune response by diminishing apoptosis
rates, decreasing defense mechanisms and finally cancer progres-
sion. It has been shown earlier that lung cancer cells carrying the
Trp149Stop (G446A) variant and expressing the truncated protein
had a reduced capability to induce apoptosis compared to cells
expressing the full-length protein [8]. This reduced apoptosis could
also be the causal factor in PCa. Our data suggest for the first time
that the predisposing effect of the CC genotype of Cys148Arg
(T442C) is related to reduced expression in immune system cells
(lymphoblasts) rather than in tumor cells where ARLTS1
expression is naturally very low.
Like all other organs, the normal prostate contains endogenous
inflammatory cells and immune response mechanisms. Conse-
quently, the function of ARLTS1 may not exclusively be based on
tumor suppression as suggested before, but also on immune
response functions that occur either locally in prostate or in
peripheral tissues. This is in line with the findings that PCa is a
very heterogeneous disease and different mechanisms of cancer
progression may occur.
Taken together, association and expression analyses of the
Cys148Arg (T442C) CC genotype and PCa risk suggest that
ARLTS1 Cys148Arg (T442C) variant has a role in PCa
predisposition and ARLTS1 functions via immune system process-
es.
Supporting Information
Figure S1 Expression of ARLTS1 in the publicly avail-
able GeneSapiens database. The expression of ARLTS1 is
very low in both normal and cancer samples. In the prostate the
expression of ARLTS1 remains very low and no significant
associations could be made using gene expression data.
(TIF)
Table 3. Association of the Cys148Arg (T442C) variant with clinicopathologic variables of prostate cancer patients.
Familial cases Unselected cases
No. of subjects 212 1848
Aggressive disease
No. of subjects 121 975
TT 40 281
TC 57 471
CC 24 223
OR (one-sided 95% CI), P value [CC] vs. [TT+TC] 0.62 (0.35 - infinity), 0.95 1.28 (1.05 - infinity), 0.02
doi:10.1371/journal.pone.0026595.t003
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(TIF)
Table S1 Clinicopatholgic variables of prostate cancer
patients.
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